Innovation Potential in Mental Health
Rising awareness and emergence of differentiated solutions for multiple psychiatric and mental health conditions is an ongoing theme of innovation in pharma but also adjacent and “convergence” fields in healthcare. Increasing incidence, certainly exacerbated by lockdowns and other measures implemented to curtail the spread of COVID-19, and the significant lack of innovation in the past represent the key ingredients for a resurgence, which is currently emerging.
The Evolving Digital Health Landscape
Capital allocation towards innovative health-tech solutions has fuelled an increase in adoption of digital technologies. We outline a few current themes and future trends in the area.
2021 in Retrospect and 2022 Outlook
A month into 2022 and all virtual “JPM meetings” completed, we took a moment to reflect on the past
The Brexit Deal – Shot in the Arm or Kick in the Teeth for the Pharma Sector?
The UK Government and EU Commission trumpeted their last minute Brexit trade deal, struck at the end of December, as comprehensive, the biggest yet. Even allowing for the hyperbole of politicians, a closer inspection of the EU-UK Trade and Cooperation Agreement (TCA) renders these statements illusory for the pharma sector. In this article we summarise the extent to which the TCA really assists businesses in the sector to overcome the separation of the UK and the EU into two separate markets:
Biopharma Partnering: 2021 – Virtual Reality?
The start of a new year in healthcare has over the past decades been characterized by back-to-back meetings spread across hotel rooms in San Francisco where the industry’s annual gathering had taken place, not to say had been celebrated. Nobody knows if or when we will return to holding physical meetings. What the pandemic has shown us all is that a lot of time can be saved when interacting virtually:
Biopharma Partnering: Striking a Deal with Big Pharma
As what used to be healthcare’s busiest meetings week is going to be a week of virtual interaction around the globe, we thought it worthwhile to share a few considerations on partnering between biotech and large pharma from the perspective of the developing biotech…
Biopharma Partnering: IPOs and Partnering
An initial Public Offering has for decades been the endgame for an aspiring biotech company. Thinking back just 10 years, an IPO was conceivable generally only once a company had successfully brought at least one lead therapeutic into late-stage clinical trials and the pipeline was robust. Today this has changed…
Biopharma Partnering: When To Partner
In late spring when apple trees are filled with young fruits, the best way to ensure a healthy harvest in autumn is to thin out the fruits, which in turn strengthens the tree and helps the remaining fruits grow and ripen.In late spring when apple trees are filled with young fruits, the best way to ensure a healthy harvest in autumn is to thin out the fruits, which in turn strengthens the tree and helps the remaining fruits grow and ripen.While the gardener knows that the autumn harvest will be stronger for doing it, the thinning out process is painful every time…
Biopharma Partnering: Dating Well Before Marriage Serves Its Purpose
For most emerging bio-pharma or medtech companies, establishing a development or commercialization partnership is a core component of their strategic plan, and, sealing the deal is cause for much celebration. While hard work and a number of all-nighters may go into signing an agreement, ensuring the partnership achieves its objectives and sails across the finish line is often harder, and often a bumpy ride…
Biopharma Partnering: A Fine Art
The majority of pharma and biotech venture creations are aimed at one or both of two fundamental objectives, bringing a novel therapeutic to patients and generating returns for their founders and investors. Often, pathways are poorly understood by the bootstrap team, and professional “help” is being sought from incubators, boards, investors and advisors, embedding possibly conflicting perspectives and goals into the core fabric of the company.